Lack of early efficacy for Translate Bio's mRNA-based cystic fibrosis drug raises some big questions

Max Gelman

Senior Editor

Looking to bring mRNA therapeutics to cystic fibrosis, Translate Bio revealed its second interim analysis in a Phase I/II study showing their experimental drug to …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Lack of early efficacy for Translate Bio's mRNA-based cystic fibrosis drug raises some big questions

Max Gelman

Senior Editor

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Will CRISPR matter?

FDA says Ozempic, Wegovy shortage is over

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Lack of ear­ly ef­fi­ca­cy for Trans­late Bio's mR­NA-based cys­tic fi­bro­sis drug rais­es some big ques­tions

Senior Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Lack of early efficacy for Translate Bio's mRNA-based cystic fibrosis drug raises some big questions